Clinical Trials

    A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia

    Investigator: Shilpan Shah

    Study Coordinator: Pauline Ngban

    Status: Enrolling

    ClinicalTrials.gov Number: NCT04811560

    Phone: 346.260.9908

    Protocol Number: PRO00038342

    Description


    The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.